CXBladder is a genomic urine test designed to detect or monitor bladder cancer in patients with hematuria or a history of urothelial carcinoma.
Non-Invasive and Painless: Simple urine sample collection – no catheter or cystoscopy needed for initial evaluation
Early and Accurate Detection: Identifies bladder cancer with high sensitivity and specificity
Reduces Unnecessary Procedures: Helps rule out cancer and avoid diagnostic cystoscopy in low-risk patients
Multiple Use Cases: Different test versions tailored for diagnosis, surveillance, and monitoring
Fast Results: Lab turnaround in just a few business days
CXBladder uses advanced molecular technology to measure the expression of five mRNA biomarkers in urine associated with bladder cancer.
It provides actionable insights for both initial diagnosis and ongoing follow-up in patients with previous bladder cancer.
A fresh urine sample is collected at the clinic or at home using a special kit
The sample is sent to a certified laboratory for analysis
Five cancer-related biomarkers are analyzed using RT-PCR
A clear result is provided to the physician within a few business days
Patients presenting with hematuria (blood in urine)
Individuals at risk for bladder cancer based on age, smoking history, or occupational exposure
Patients with prior urothelial carcinoma under regular surveillance
Clinicians looking to avoid unnecessary cystoscopies in low-risk patients
